Search by Ticker
Abbvie Inc. (NYSE:ABBV)
The following stock analysis is based on 10.2 years of data (i.e. since Jan 02, 2013). All the stock history has been downloaded.
Abbvie Inc. trades on the NYSE exchange in USD dollars.
It is in the sector.
It is currently trading at $159.37 ($157.92 the previous day).It pays a 3.62% dividend.
The next reporting date is in 26 days (2023 04 27).
CNN estimates profits for the upcoming quarter will be $2.56 per share ($12.1B). The current Canada / US exchange rate is 1.3511.
Over the past 12 months, $0 worth of shares have been purchased and $148340364 worth of shares have been sold by insiders.
The year over year average increase is 10.7% per year assuming steady exponential growth. The actual 5 year average is 12.8. Details on the individual increase in one year intervals is provided below.
|Past Performance||Average Price||Percent Change|
|1 year||150.50686785714||27.9||+ Above Average|
|2 year||117.71300769231||21.3||+ Above Average|
|3 year||97.016304624277||21.9||+ Above Average|
|4 year||79.607105913979||-11.9||- Below Average|
|5 year||90.360038167939||4.8||- Below Average|
The worst drop it has had in recent years is -48.5%. It has a dropping shape to the stock curve, which means the stock has to be watched closely. If the financials are good, it could be very profitable, however if not it may not recover and should be sold.
The Top Healthcare Stocks to Buy With $100Fri, 31 Mar 2023 14:00:00 A common misconception is that you need a lot of money to invest in the stock market. Let's look at three healthcare stocks that can be purchased for $100 and have good prospects to grow over time. The stock hasn't been ...... Read Full Article
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVieFri, 31 Mar 2023 12:50:00 AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). Let's examine the data from the clinical trial and the U.S. UC market ...... Read Full Article
Starter Stock Portfolio: 15 Safe Stocks To BuyThu, 30 Mar 2023 15:02:16 In this article, we will take a look at the 15 safe stocks to buy. To see more such companies, go directly to Starter Stock Portfolio: 5 Safe Stocks To Buy. Amid the current market turmoil which seems to have no end ...... Read Full Article
2 High-Yielding Dividend Investments to Buy for the Long HaulThu, 30 Mar 2023 11:45:00 Both of these stocks are Dividend Kings, and their payouts are likely to continue rising in the future.... Read Full Article
12 Most Promising Healthcare Stocks According to AnalystsWed, 29 Mar 2023 20:40:54 In this article, we will take a look at the 12 most promising healthcare stocks according to analysts. To see more such companies, go directly to 5 Most Promising Healthcare Stocks According to Analysts. 2023 is turning out to be a horrific year ...... Read Full Article
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVieWed, 29 Mar 2023 18:00:00 Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbuster drug on the horizon.... Read Full Article
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023Wed, 29 Mar 2023 13:00:00 Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock ...... Read Full Article
Better Growth Stock: AbbVie vs. PfizerWed, 29 Mar 2023 11:30:00 AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation ...... Read Full Article
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma PartnersTue, 28 Mar 2023 17:35:14 CytomX Therapeutics Inc (NASDAQ: CTMX) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV) decided not to advance the drug into additional studies. CytomX and AbbVie have also concluded their research activities under ...... Read Full Article
2 Relatively Safe Dividend Stocks You Won't Regret OwningTue, 28 Mar 2023 14:07:00 While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their history of effective competition and their management's skill at ...... Read Full Article
This Is the Best Dividend ETF You Can BuyTue, 28 Mar 2023 12:13:00 The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position.... Read Full Article
CIBC introduces additional Canadian Depositary Receipts ("CDRs")Tue, 28 Mar 2023 12:00:00 CIBC today announced the addition of six new Canadian Depositary Receipts ("CDRs"), now listed on the NEO Exchange.... Read Full Article
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should KnowMon, 27 Mar 2023 21:45:09 In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day.... Read Full Article
Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt ResponsiblyMon, 27 Mar 2023 12:00:35 David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...... Read Full Article
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli LillyMon, 27 Mar 2023 11:41:11 Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.... Read Full Article
Who Are Pfizer's (PFE) Main Competitors?Sat, 25 Mar 2023 17:38:05 Pfizer's biggest competitors in the global pharmaceutical industry are Johnson and Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.... Read Full Article
Better Buy: AbbVie vs. Johnson and JohnsonSat, 25 Mar 2023 09:30:00 AbbVie (NYSE: ABBV) and Johnson and Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing ...... Read Full Article
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRLFri, 24 Mar 2023 13:04:01 Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951... Read Full Article
The price of Humira's biosimilars can uncloak the secret villain of US drug pricingThu, 23 Mar 2023 14:30:00 Pharmaceutical giant AbbVie was able to delay competition to its blockbuster arthritis drug, Humira, into the US market for many years. But Americans can finally choose from one of several arthritis biosimilars, as generics for complex molecule drugs are known.... Read Full Article
2 High-Yield Dividend Stocks You Won't Regret Buying Right NowThu, 23 Mar 2023 14:00:00 High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. Which high-yield dividend stocks are worth buying right now? Read on to find out more about these above-average passive income opportunities.... Read Full Article